VAN ZUILEN WILFRED 4

What Happened
Wilfred van Zuilen, Group President, EMEA for Zimmer Biomet (ZBH), was awarded 4,843 performance-based restricted stock units (RSUs) effective Feb 19, 2026. The filing shows an acquisition of 4,843 derivative securities at $0.00 (code A — award/grant). These RSUs were earned based on performance conditions for the 2023–2025 performance period and are scheduled to vest on March 6, 2026. This is a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date reported: February 19, 2026; Form 4 filed February 23, 2026. No indication in the filing that it was late.
• Amount: 4,843 RSUs; reported price $0.00 (derivative award).
• Footnote summary: F1 — each RSU converts to one share of common stock upon vesting. F2 — these were performance-based RSUs granted March 6, 2023 for the 2023–2025 performance period; actual payout determined Feb 19, 2026. Vesting date: March 6, 2026.
• Shares owned after the transaction: not disclosed in the provided filing.

Context
RSUs are a form of equity compensation that convert into actual shares at vesting; performance-based RSUs depend on pre-set goals and are routine for executives. Because this is an award from the company’s compensation program (not a market purchase or sale), it should be viewed as compensation realization rather than a direct buy/sell signal about the insider’s view of the stock.